Accessibility Menu
Sinopharm Group logo

Sinopharm Group(SEHK) 1099

Market CapHK$49.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)+31%
5 Year-24%
1 Year-17%
1 Month-11%
HK$15.50
-2.70%
-0.43Today
Sinopharm Group last closing stock price
MetricPriceDate
Last closeHKD 15.502026-08-31
Sinopharm Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.08%HKD 16.332026-08-24
1 month-10.82%HKD 17.382026-07-31
3 month-9.14%HKD 17.062026-06-02
Year to date-20.27%HKD 19.442025-12-31
1 year-16.98%HKD 18.672025-08-29
3 year-31.87%HKD 22.752023-08-31
5 year-23.65%HKD 20.302021-09-01
Since inception+30.92%HKD 12.172009-09-23

Sinopharm Group Financials at a Glance

Market Cap

HK$49.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.14T

Net Income (TTM)

CN¥13.85B

EPS (TTM)

HK$2.54

P/E Ratio

6.28

Dividend

HK$0.79

Beta (Volatility)

-0.01 (Low)

Price

HK$15.50

Volume

8,620,427

Open

HK$15.93

Previous Close

HK$15.93

Daily Range

HK$15.39 - HK$15.93

52-Week Range

HK$15.28 - HK$22.34

Estimated Earnings Date

Mar 19, 2027

1099 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sinopharm Group

Sinopharm Group Co. Ltd. is a leading entity in China's healthcare sector, focusing on the wholesale and retail distribution of pharmaceuticals, medical devices, and health-related products. Established in 2003, the company operates through four main divisions, catering to a diverse clientele including hospitals, pharmacies, and clinics.

Products and Services
  • Pharmaceutical distribution to hospitals and pharmacies
  • Retail pharmacy chain with over 10,000 locations
  • Manufacturing and sale of medical devices and health products
Growth Outlook
  • Strategic alliance with I-Mab enhances market entry capabilities
  • Continued expansion in retail pharmacy locations expected
  • Focus on technological training and consulting services for healthcare
Financial Highlights
  • Recent quarterly revenue of 278.9 billion CNY, showing resilience
  • Trailing twelve months (TTM) net income margin at 1.24%
  • Dividend yield of approximately 4.84%, indicating shareholder returns
Sinopharm Group Co. Ltd. has established itself as a significant player in the healthcare distribution market in China. The company's diverse product offerings and extensive distribution network position it well for future growth. The strategic partnership with I-Mab is expected to bolster its market presence and enhance operational efficiencies. Recent financial performance reflects stability, with a solid revenue base and a commitment to returning value to shareholders through dividends. The company's focus on expanding its retail pharmacy footprint and enhancing service offerings through technology and consulting further underscores its growth potential in the evolving healthcare landscape.
AI Generated • Aug 25, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

94,910

Website

ir.sinopharmgroup.com.cn

Headquarters

Shanghai, SH 200023, CN

1099 Financials

Key Financial Metrics (TTM)

Gross Margin

7.03%

Operating Margin

2.95%

Net Income Margin

1.24%

Return on Equity

8.33%

Return on Capital

8.33%

Return on Assets

1.74%

Earnings Yield

15.92%

Dividend Yield

4.96%

Payout Ratio

60.03%

Stock Overview

Market Cap

HK$49.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.12B

Volume

8.62M

Avg. Volume

5.81M

Financials (TTM)

Gross Profit

CN¥83.00B

Operating Income

CN¥31.87B

EBITDA

CN¥41.16B

Operating Cash Flow

CN¥23.60B

Capital Expenditure

-CN¥4.01B

Free Cash Flow

CN¥19.59B

Cash & ST Invst.

CN¥41.88B

Total Debt

CN¥113.77B

Sinopharm Group Performance Analysis

Sinopharm Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 642,080,347,9092.2%
20232023-12-31CNY 659,208,174,5332.7%
20242024-12-31CNY 633,737,433,839-3.9%
20252025-12-31CNY 623,783,004,695-1.6%
Sinopharm Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-1.7%
Q22025-06-30-1.3%
Q42025-12-311.1%
Q22026-06-30-3.5%
Sinopharm Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 3.186.0%
20232023-12-31CNY 3.210.9%
20242024-12-31CNY 2.45-23.6%
20252025-12-31CNY 2.491.5%
Sinopharm Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-10.1%
Q22025-06-303.7%
Q42025-12-316.3%
Q22026-06-30-9.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥278.90B

-5.4%

Gross Profit

CN¥18.59B

-15.3%

Gross Margin

6.66%

N/A

Market Cap

HK$49.71BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$523.78K

N/A

Employees

94,910

N/A

Net Income

CN¥3.36B

-9.4%

EBITDA

CN¥10.13B

+6.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥41.88B

-3.4%

Total Debt

CN¥113.77B

+12.6%

Accounts Receivable

CN¥237.49B

-2.0%

Inventory

CN¥66.63B

-3.2%

Long Term Debt

CN¥6.55B

-66.6%

Short Term Debt

CN¥107.22B

+31.6%

Return on Assets

1.74%

N/A

Return on Invested Capital

11.46%

N/A

Free Cash Flow

CN¥45.28B

-23.6%

Operating Cash Flow

CN¥46.16B

-23.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 1099

What is the current price of Sinopharm Group?

Sinopharm Group is trading at HK$15.50 per share.

What is the 52-week range for Sinopharm Group?

Over the past 52 weeks, Sinopharm Group has traded between HK$15.28 and HK$22.34.

How much debt does Sinopharm Group have?

As of the most recent reporting period, Sinopharm Group reported total debt of CN¥111.70B.

How much cash does Sinopharm Group have on hand?

Sinopharm Group reported CN¥65.64B in cash and cash equivalents in its most recent financial results.

What is Sinopharm Group’s dividend yield?

Sinopharm Group currently has a dividend yield of 4.96%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services